ArticleESC heart failure2021
Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension.
Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Unraveling the impact of nitric oxide, almitrine, and their combination in COVID-19 (at the edge of sepsis) patients: a systematic review.Frontiers in pharmacology · 2023Pooled it
- Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review.Indian journal of pharmacologyPooled it
- Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study.Critical care (London, England) · 2024Article
- Potential therapeutic targets for COVID-19 complicated with pulmonary hypertension: a bioinformatics and early validation study.Scientific reports · 2024Article
- A Comprehensive Review of Inhaled Nitric Oxide Therapy: Current Trends, Challenges, and Future Directions.Cureus · 2024Review
- Understanding COVID-19-associated endothelial dysfunction: role of PIEZO1 as a potential therapeutic target.Frontiers in immunology · 2024Review
- The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection.International journal of molecular sciences · 2023Review
- Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: the black side of the moon.Molecular and cellular biochemistry · 2023Article
- Inhaled nitric oxide in patients with acute respiratory distress syndrome caused by COVID-19: treatment modalities, clinical response, and outcomes.Annals of intensive care · 2023Article
- Inhaled nitric oxide: can it serve as a savior for COVID-19 and related respiratory and cardiovascular diseases?Frontiers in microbiology · 2023Review
- Utility of NO and HNitric oxide : biology and chemistry · 2022Review
- Inhaled Nitric Oxide in Acute Severe Pulmonary Hypertension and Severe Acute Respiratory Distress Syndrome Secondary to COVID-19 Pneumonia: A Case Report.The American journal of case reports · 2022Article
- More questions than answers for the use of inhaled nitric oxide in COVID-19.Nitric oxide : biology and chemistry · 2022Review
- High Doses of Inhaled Nitric Oxide as an Innovative Antimicrobial Strategy for Lung Infections.Biomedicines · 2022Review
- Editorial commentary: Could shear stress mimetics delay complications in COVID-19?Trends in cardiovascular medicine · 2022Article
- Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges.Frontiers in medicine · 2022Review
- COVID-19 Acute Respiratory Distress Syndrome and Pulmonary Embolism: A Case Report of Nebulized Nitroglycerin and Systemic Thrombolysis For Right Ventricular Failure.The Journal of emergency medicine · 2021Article
- Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension.ESC heart failure · 2021Article
- Bioactivity of Inhaled Methane and Interactions With Other Biological Gases.Frontiers in cell and developmental biology · 2021Review
- A Novel Non-Invasive Device for the Assessment of Central Venous Pressure in Hospital, Office and Home.Medical devices (Auckland, N.Z.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
aimsThis study aims to analyse whether inhaled nitric oxide (iNO) was beneficial in the treatment of coronavirus disease 2019 (COVID-19) patients with pulmonary hypertension. METHODS AND
resultsFive critically ill COVID-19 patients with pulmonary hypertension designated Cases 1-5 were retrospectively included. Clinical data before and after iNO treatment were serially collected and compared between patients with or without iNO treatment. The five cases experienced pulmonary artery systolic pressure (PASP) elevation (≥50 mmHg) at 30, 24, 33, 23, and 24 days after illness onset (d.a.o), respectively. Cases 1-3 received iNO treatment on the 24th, 13th, and 1st day after the first elevation of PASP, with concentrations varied from 10 to 20 ppm based on the changes of PASP and blood pressure for 10, 9, and 5 days, respectively. Upon iNO treatment, PASP of Cases 1 and 2 returned to normal on the 10th day and 1st day, and maintained between 50 and 58 mmHg in Case 3. Pa0
conclusionsInhaled nitric oxide treatment was beneficial in reducing and stabilizing the PASP and might also reduce the risk of right heart failure in COVID-19 with pulmonary hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.